Business
HealthEquity administers health savings accounts and related benefits.
HealthEquity grew revenue, remained profitable, generated positive free cash flow at a 24.6% operating margin. Strong margins and free cash flow were supported by a favorable operating and statistical profile.
The read at a glance✓ Audited against SEC data
- Growth — Revenue grew 9.5%OK
- Profitability — Net income grew 122.5% to $215.201M from $96.703MOK
- Cash flow — Free cash flow grew 34.7% to $455.125M from $337.772MOK
- Margins — Operating margin expanded 1102 bps to 24.55%OK
- Accounting — Strong margins and free cash flow were supported by a favorable operating and statistical profileNote
- Insiders — 0 purchases and 11 salesWatch
Where the revenue comes from
Fiscal 2026, as HEALTHEQUITY, INC. reports it. History and quarterly detail are in the app.
- Custodial$636.8M
- Service$485.0M
- Interchange$191.6M
Leadership changes
From HEALTHEQUITY, INC.'s own filings, the day they're filed.
- Sunil Rajasekar · President · departureeff. 2026-04-17
- Eli Rosner · Chief Technology Officer · departureeff. 2026-04-17
- Jon Kessler · departureeff. 2025-04-30
Latest filings
- 8-K · Company announcement2026-08-27
- 10-Q · Quarterly report2026-08-27
- 8-K · Company announcement2026-06-26
- 8-K · Company announcement2026-05-28
- 10-Q · Quarterly report2026-05-28
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about HEALTHEQUITY, INC., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.